A new national survey found that while many Americans use a device to monitor their heart, few share that data with their doctor.

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

Much has changed since the 2013 document came out, with new information on pacing devices, techniques, and more.

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, ...

Smart healthtech wearable devices are trending but are these effective and accurate We reached out to a doctor who explained ...

Results from the single-arm trial saw 63.5% of patients able to avoid the symptoms of Atrial fibrillation over the course of ...

Boston Scientific Corporation (NYSE: BSX) today announced data supporting the use of the FARAPULSE™ Pulsed Field Ablation ...

Medtronic (NYSE: MDT) today reported study results highlighting AFib detection with its Linq family of insertable cardiac monitors (ICM).

Medtronic CEO Geoff Martha discusses innovations such as pulse field ablation, renal denervation, DBS, TAVR, diabetes tech ...

The global cardiovascular devices market, valued at US$ 72.83 billion in 2023, is forecasted to grow at a robust CAGR of 7.3%, reaching US$ ...